ROS are also continuously generated by enzymatic reactions involving cyclooxygenases, NADPH oxidases (NOXs), xanthine oxidases and lipoxygenases and through the iron-catalyzed Fenton reaction
The main benefits of GLP-1 therapy include: Enhanced insulin secretion in response to meals Reduced glucagon release, preventing high blood sugar levels Slowed gastric emptying, leading to prolonged satiety Decreased appetite, which may help with weight loss Currently available GLP-1 receptor agonists include drugs like liraglutide (Victoza), semaglutide (Ozempic, Wegovy), exenatide (Byetta), and dulaglutide (Trulicity)
But this route has not been yet approved by FDA
warehouses in Florida, North Carolina, and California
New Eng J Med 346(6), p.393-403